An arbitration panel has ruled that Prime Medicine did not breach its partnership agreement with Beam Therapeutics by developing a treatment for a rare AATD liver disease. The decision removes a major legal overhang for Prime, allowing it to advance the gene editing program without restriction.
The conflict centered on Prime's alpha-1 antitrypsin deficiency (AATD) candidate, which Beam had argued fell under the scope of their collaboration. The panel rejected Beam's claim, stating Prime's work was independent of the partnership's terms. Shares of Prime rose on the news, while Beam's stock slipped slightly.
Separately, the FDA reversed a prior decision on a therapy from Saol Therapeutics, marking what the company described as the latest post-Makary reversal. The agency had previously declined to approve the treatment, but now appears to have changed course following additional data review.
In Europe, regulators are using a pancreatic cancer drug from Cyllene as a test case for a new review framework designed to accelerate access for innovative therapies. The EMA is evaluating daraxonrasib under the Priority Medicines (PRIME) scheme, which could shorten approval timelines if the drug meets efficacy benchmarks.
Counter-argument: Some analysts caution that the arbitration win does not guarantee Prime's AATD program will succeed clinically, and the broader gene therapy field still faces safety and delivery challenges. Additionally, the FDA's reversal pattern under the current administration has drawn criticism for creating regulatory unpredictability.